Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU sunscreen guidance

This article was originally published in The Tan Sheet

Executive Summary

The European Commission expects to adopt a recommendation for sunscreen labeling guidance for industry that aims to ensure a "standardized simple and understandable labeling of sunscreen products," according to an announcement May 4. In addition to ensuring UVA protection is indicated "in a uniform way based on standardized testing methods," the guidance will recommend that product labeling "giving the impression of total protection, such as 'sunblocker' should disappear," and that labels "bear clear and understandable warnings and usage instructions for the consumer on how to use a sunscreen product correctly," the agency notes. Comments are now being accepted on the draft recommendations. FDA is working to publish UVA guidelines under the partially-stayed OTC sunscreen final monograph this year, as recently urged by Congress (1"The Tan Sheet" Sept. 26, 2005, p. 4)...

You may also be interested in...



EU Sheds Light On Recommended Sunscreen Labeling Options

Sunscreen protection levels would be ranked in four categories - low, medium, high or very high - on product labeling under a proposal by the European Commission

Spending Bill Addresses Conflict Waivers, Sunscreen Monograph

FDA will be required to publicly disclose the rationale behind any advisory committee conflict of interest waivers under an amendment to the Senate version of the agency's spending bill

Novartis Teams Up With CureVac To Make COVID-19 Vaccine

The Swiss major, which is already signed up to help produce Pfizer and BioNTech's COVID-19 vaccine, is offering its services to CureVac to produce its mRNA vaccine.

Topics

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel